Lung Cancer
Find out more about lung cancer, the second most common cancer worldwide, that claims more lives each year than any other type.
Search
Small Cell Lung Cancer
Discover more about small cell lung cancer, including its symptoms and treatment options.
Non-small cell lung cancer
Discover more about non-small cell lung cancer, including its symptoms and treatment options.
Overcoming stigma and advancing lung cancer advocacy
Lung cancer advocates highlight the need to overcome stigma, access reliable info, and implement early diagnosis and screening.
Expert insights: the top online lung cancer questions answered
As part of Big Little Things, we teamed up with top patient representatives from around the world to answer the most searched questions about lung cancer.
Breaking prejudice in lung cancer
At Boehringer Ingelheim, addressing patient needs and fighting stigma in lung cancer care are two focus topics of the patient engagement team in oncology.
Larry’s Story: Advocating for people with lung cancer
In 2013, Larry was diagnosed with non-small cell lung cancer. Learn how his diagnosis led him on a journey of patient advocacy for others with cancer.
Facing lung cancer
Keith and Heather talk about their experiences of facing lung cancer as a family and finding purpose after treatment.
A life in a day: the reality of living with lung cancer
Within the initiative “A life in a day”, Anna-Maria spent 24 hours in the shoes of a lung cancer patient to better understand the patient experience.
Zongertinib positive results non-small cell lung cancer
Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients
expanded-collaboration-MD-Anderson
The continued collaboration aims to accelerate the development of KRAS and TRAILR2 compounds in lung cancer
Taking Cancer on Through Flavour
Recipes developed specifically for people living with cancer. Contributions from a chef, a dietitian, and a cancer survivor.
Targeting HER2 in cancer: The story of zongertinib
We discovered zongertinib, an HER2 tyrosine kinase inhibitor, being developed as a potential oral treatment for people with HER2-mutated NSCLC
Exploring innovation in interstitial lung disease (ILD)
Interstitial lung disease (ILD) describes a group of over 200 lung disorders characterized by inflammation and scarring of the interstitium of the lungs.
Interstitial lung disease in rheumatoid arthritis (RA-ILD)
Interstitial lung disease (ILD) is the most common type of lung condition associated with the systemic autoimmune disease rheumatoid arthritis (RA).
Lung Diseases
Lung Diseases
T-cell engagers: Reawakening T-cells to fight cancer
Learn how we are taking cancer on through our approach to immuno-oncology and our T-cell engagers plarform
Experiences of living with cancer
We know from speaking with people living with cancer and their loved ones, that it’s often the small moments that can be the most significant.
Boehringer Ingelheim - Life Forward
Learn how we change life for the better for people and animals.
The power of patient advocacy in cancer care
Larry, a retired US Navy veteran, and Jeff, UICC President, have more in common than a cancer diagnosis: they share a passion for patient empowerment.
Lung Repair & Regeneration Video
Lung repair & regeneration research addresses fundamental changes to lung architecture and how these changes impact lung function.
Investigational treatment slowed lung function decline in IPF
Investigational treatment slowed lung function decline in IPF
Breathing hope: fighting the lung disease pulmonary fibrosis
The animation and accompanying article aims to draw attention to and raise awareness about pulmonary fibrosis, a disease often misdiagnosed an overlooked.
Why cancer care is personal for us
At Boehringer Ingelheim, we have made a generational commitment to transforming cancer care, with the ultimate goal of curing a range of cancers.
Acquisition expands research in cancer immunology
Boehringer Ingelheim acquires Abexxa to develop novel cancer therapies by leveraging Abexxa’s unique technology and breakthrough antibody-based drugs.